Trastuzumab beyond progression in patients with HER2-positive advanced gastric adenocarcinoma: a multicenter AGEO study

INTRODUCTION: Trastuzumab in combination with platinum-based chemotherapy is the standard first-line regimen in HER2-positive advanced gastric cancer. However, there are very few data concerning efficacy of continuing trastuzumab beyond first-line progression. METHODS: This retrospective multicenter...

Descripción completa

Detalles Bibliográficos
Autores principales: Palle, Juliette, Tougeron, David, Pozet, Astrid, Soularue, Emilie, Artru, Pascal, Leroy, Florence, Dubreuil, Olivier, Sarabi, Matthieu, Williet, Nicolas, Manfredi, Sylvain, Martin-Babau, Jerome, Rebischung, Christine, Abdelghani, Meher Ben, Evesque, Ludovic, Dreanic, Johann, Hautefeuille, Vincent, Louafi, Samy, Sefrioui, David, Savinelli, Francesco, Mabro, May, Rousseau, Benoit, Lecaille, Cédric, Bouché, Olivier, Louvet, Christophe, Lecomte, Thierry, Bonnetain, Franck, Taieb, Julien, Zaanan, Aziz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5731882/
https://www.ncbi.nlm.nih.gov/pubmed/29254172
http://dx.doi.org/10.18632/oncotarget.20711

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5731882/
https://www.ncbi.nlm.nih.gov/pubmed/29254172
http://dx.doi.org/10.18632/oncotarget.20711

Ejemplares similares